Multivariate regression analysis: risk factors for hypertension, diabetes, and dyslipidemia among HCT recipients
| Risk factor . | Hypertension . | Diabetes . | Dyslipidemia . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| HR . | 95% CI . | P . | HR . | 95% CI . | P . | HR . | 95% CI . | P . | |
| Sex | |||||||||
| Male | 1.0 | 1.0 | 1.0 | ||||||
| Female | 1.1 | 0.85-1.31 | .60 | 1.3 | 0.98-1.84 | .07 | 0.9 | 0.82-1.09 | .91 |
| Ethnicity/race | |||||||||
| Non-Hispanic white | 1.0 | 1.0 | 1.0 | ||||||
| Other | 0.8 | 0.58-0.98 | .03 | 2.1 | 1.51-2.82 | < .01 | 1.1 | 0.94-1.38 | .18 |
| Age at HCT, y | |||||||||
| < 35 | 1.0 | 1.0 | 1.0 | ||||||
| 35-55 | 1.6 | 1.24-2.10 | < .01 | 1.7 | 1.16-2.57 | < .01 | 1.7 | 1.38-2.17 | < .01 |
| > 55 | 2.6 | 1.88-3.47 | < .01 | 4.1 | 2.63-6.49 | < .01 | 2.2 | 1.69-2.88 | < .01 |
| BMI at HCT | |||||||||
| < 30 kg/m2 | 1.0 | 1.0 | 1.0 | ||||||
| ≥ 30 kg/m2 | 1.6 | 1.20-2.02 | < .01 | 2.0 | 1.44-2.73 | < .01 | 1.5 | 1.18-1.79 | < .01 |
| Conditioning | |||||||||
| Chemotherapy | 1.0 | 1.0 | 1.0 | ||||||
| Chemotherapy + TBI | 1.0 | 0.79-1.26 | .98 | 1.5 | 1.10-2.16 | .01 | 1.4 | 1.14-1.70 | < .01 |
| HCT Type | |||||||||
| Autologous | 1.0 | 1.0 | 1.0 | ||||||
| Allogeneic, no aGvHD* | 5.2 | 3.89-7.01 | < .01 | 2.6 | 1.75-3.84 | < .01 | 2.2 | 1.77-2.76 | < .01 |
| Allogeneic, aGvHD grade II-IV | 9.1 | 6.57-12.19 | < .01 | 5.8 | 3.93-8.53 | < .01 | 3.2 | 2.49-4.04 | < .01 |
| Risk factor . | Hypertension . | Diabetes . | Dyslipidemia . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| HR . | 95% CI . | P . | HR . | 95% CI . | P . | HR . | 95% CI . | P . | |
| Sex | |||||||||
| Male | 1.0 | 1.0 | 1.0 | ||||||
| Female | 1.1 | 0.85-1.31 | .60 | 1.3 | 0.98-1.84 | .07 | 0.9 | 0.82-1.09 | .91 |
| Ethnicity/race | |||||||||
| Non-Hispanic white | 1.0 | 1.0 | 1.0 | ||||||
| Other | 0.8 | 0.58-0.98 | .03 | 2.1 | 1.51-2.82 | < .01 | 1.1 | 0.94-1.38 | .18 |
| Age at HCT, y | |||||||||
| < 35 | 1.0 | 1.0 | 1.0 | ||||||
| 35-55 | 1.6 | 1.24-2.10 | < .01 | 1.7 | 1.16-2.57 | < .01 | 1.7 | 1.38-2.17 | < .01 |
| > 55 | 2.6 | 1.88-3.47 | < .01 | 4.1 | 2.63-6.49 | < .01 | 2.2 | 1.69-2.88 | < .01 |
| BMI at HCT | |||||||||
| < 30 kg/m2 | 1.0 | 1.0 | 1.0 | ||||||
| ≥ 30 kg/m2 | 1.6 | 1.20-2.02 | < .01 | 2.0 | 1.44-2.73 | < .01 | 1.5 | 1.18-1.79 | < .01 |
| Conditioning | |||||||||
| Chemotherapy | 1.0 | 1.0 | 1.0 | ||||||
| Chemotherapy + TBI | 1.0 | 0.79-1.26 | .98 | 1.5 | 1.10-2.16 | .01 | 1.4 | 1.14-1.70 | < .01 |
| HCT Type | |||||||||
| Autologous | 1.0 | 1.0 | 1.0 | ||||||
| Allogeneic, no aGvHD* | 5.2 | 3.89-7.01 | < .01 | 2.6 | 1.75-3.84 | < .01 | 2.2 | 1.77-2.76 | < .01 |
| Allogeneic, aGvHD grade II-IV | 9.1 | 6.57-12.19 | < .01 | 5.8 | 3.93-8.53 | < .01 | 3.2 | 2.49-4.04 | < .01 |
HR indicates hazard ratio.
Includes no aGvHD or grade I aGvHD.